Pfizer Stock Forecast: 15% Upside as Its Pipeline Delivers New Wins

Key Stats for PFE Stock

• Past week’s performance: Consolidating
• 52-week range: $23 to $29
• Valuation model target price: $29
• Implied upside: 15% over 2.4 years

Yield alone doesn’t tell the whole story. See Pfizer’s full return model on TIKR (It’s free) >>>

Pipeline Wins Are Doing the Talking

Pfizer (PFE) has traded in a tight range near $25 this week, but the underlying news flow points to a company slowly rebuilding its growth story beyond the pandemic era. Two developments stand out most for investors weighing the stock today.

First, Pfizer’s oral drug Litfulo restored skin pigmentation in patients with nonsegmental vitiligo across two late-stage trials, with significantly more patients achieving meaningful facial and total-body repigmentation than those on placebo after 52 weeks. Vitiligo currently has few approved treatment options, so a positive readout here expands Pfizer’s addressable pipeline meaningfully.

Second, the European Commission authorized Pfizer and BioNTech’s updated COVID-19 vaccine for the 2026-2027 season, covering everyone from six months of age and up across the EU. That approval secures a recurring, if smaller, revenue stream heading into the fall vaccination season.

Elsewhere, Pfizer’s prostate cancer combination of Talzenna and Xtandi received FDA priority review, and its Padcev-Keytruda combination gained approval for bladder cancer treatment. Both wins reinforce Pfizer’s push into oncology as a growth pillar to offset fading COVID-era demand.

On the regulatory side, a U.S. House committee is probing Pfizer along with other drugmakers over China-based clinical trial practices, a headline risk worth monitoring even though it hasn’t materially affected the stock so far. Pfizer confirmed receiving the inquiry letter but has not disclosed specific findings.

A Pfizer inflammation and immunology executive said Litfulo could become a new treatment option that meaningfully improves and maintains repigmentation for vitiligo patients, underscoring how the company is framing its pipeline as the next leg of its turnaround. If Pfizer stock keeps stacking pipeline wins ahead of its August 4 earnings report, the current valuation may start looking too conservative.

Follow every FDA decision on Pfizer’s pipeline in real time with TIKR’s news feed (It’s free) >>>

Value Stock or Value Trap?

Under valuation model assumptions realized through 12/31/28, the stock is modeled using:

• Revenue Growth (CAGR): (1.6%)
• Operating Margins: 35.1%
• Exit P/E Multiple: 8.8x

Based on these inputs, the model estimates a target price of $29, implying a 15% total return from the current share price and a 5.9% annualized return over the next 2.4 years.

Pfizer’s model output lands right at the edge of what counts as an attractive setup, and that reflects a genuinely mixed picture. Revenue growth is projected to decline slightly, since Pfizer is still working through the aftermath of collapsing COVID-era demand and looming patent expirations on key drugs.

Margins remain a real strength. Operating margin near 35% is well above most pharma peers, supported by a diversified portfolio spanning oncology, vaccines, and specialty medicines. That profitability is what allows Pfizer to keep funding one of the highest dividend yields in the S&P 500, currently near 6.9%.

The exit multiple of 8.8x is unusually low for a large pharma name, and that discount is exactly why some investors see Pfizer as undervalued rather than a value trap. The healthcare sector’s average forward multiple sits closer to 18x, so Pfizer trades at less than half that benchmark despite its scale and pipeline depth.

Whether the stock re-rates higher depends heavily on execution. If oncology approvals like the Talzenna-Xtandi combination and continued vitiligo data keep landing, Pfizer could gradually shift the market’s perception from a shrinking legacy business to a diversified grower again.

See exactly how Pfizer’s 8.8x multiple compares to the healthcare sector average on TIKR >>>

Pfizer vs. Bristol Myers and Merck

Bristol Myers Squibb (BMY) is Pfizer’s closest comparison on the dividend front, and the two stocks are frequently pitted against each other by income investors. Pfizer’s forward dividend yield of roughly 6.7% to 6.9% comfortably beats Bristol Myers’ yield near 4.4% to 4.6%, though Pfizer’s payout ratio above 60% is notably higher than Bristol Myers’ roughly 40%, raising more questions about long-term dividend durability.

Both stocks trade at similarly cheap multiples, generally just under 9x forward earnings. This reflects shared concerns about patent cliffs hitting key drugs like Eliquis, co-marketed by both companies, by decade’s end. Bristol Myers recently raised its 2026 forecast on strength from Eliquis and newer oncology medicines. This suggests the patent cliff narrative may be overstated for both names.

Merck (MRK) offers a useful third comparison point. Merck’s dividend yield sits lower, near 3.7%, but its payout ratio is far more conservative, giving it more room to protect and grow the dividend even as its own Keytruda patent cliff approaches later this decade.

Where Pfizer stands out is deal activity. The recently closed Metsera acquisition, worth up to $10.6 billion including earnouts, pushes Pfizer into the obesity drug market. Merck and Bristol Myers currently have less direct exposure in this space. This gives Pfizer a distinct growth lever its peers lack.

See how Pfizer’s lung-cancer miss and CFO exit reshape the 2026 setup >>>

What’s Driving PFE Stock Going Forward?

The most immediate catalyst is Pfizer’s Q2 2026 earnings report on August 4, where investors will focus on non-COVID product growth and any updated full-year guidance following the CFO transition earlier this year.

Regulatory catalysts remain dense. The FDA is expected to rule soon on the Talzenna–Xtandi prostate cancer combination, following its priority review designation. Meanwhile, continued vitiligo trial data from Litfulo could support a regulatory filing later this year.

The Metsera integration is worth watching closely, since successfully building out an obesity pipeline would give Pfizer a genuine growth story beyond its traditional oncology and vaccine franchises, an area where competitors currently have a head start.

Finally, the House committee’s inquiry into China-based clinical trials is a headline risk that could resurface. A clean resolution would remove an overhang, while any expanded investigation could weigh on sentiment even without changing Pfizer’s underlying fundamentals.

Estimate a company’s fair value instantly (Free with TIKR) >>>

Should You Invest in Pfizer?

The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.

Pull up PFE, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.

You can build a free watchlist to track PFE alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.

Analyze PFE stock on TIKR Free→

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!